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A high-performance thin-layer chromatographic method for simultaneous determination
of nadifloxacin, mometasone furoate, and miconazole nitrate was developed and validated
as per International Conference on Harmonization guidelines. High-performance thin-
layer chromatographic separation was performed on aluminum plates precoated with
silica gel 60F254 and methanol:ethyl acetate:toluene: acetonitrile:3M ammonium formate in
water (1:2.5:6.0:0.3:0.2, % v/v) as optimized mobile phase at detection wavelength of
224 nm. The retardation factor (Rf) values for nadifloxacin, mometasone furoate, and mi-
conazole nitrate were 0.23, 0.70, and 0.59, respectively. Percent recoveries in terms of ac-
curacy for the marketed formulation were found to be 98.35e99.76%, 99.36e99.65%, and
99.16e100.25% for nadifloxacin, mometasone furoate, and miconazole nitrate, respectively.
The pooled percent relative standard deviation for repeatability and intermediate precision
studies was found to be < 2% for three target analytes. The effect of four independent
variables, methanol content in total mobile phase, wavelength, chamber saturation time,
and solvent front, was evaluated by fractional factorial design for robustness testing.
Amongst all four factors, volume of methanol in mobile phase appeared to have a possibly
significant effect on retention factor of miconazole nitrate compared with the other two
drugs nadifloxacin and mometasone furoate, and therefore it was important to be carefully
controlled. In summary, a novel, simple, accurate, reproducible, and robust high-
performance thin-layer chromatographic method was developed, which would be of use
in quality control of these cream formulations.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).ity Assurance, Anand Pharmacy College, Anand, Gujarat, 388001, India.
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Nadifloxacin (ND), chemically (RS)-9-fluoro-8-(4-hydroxy-
piperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido
[3,2,1-ij] quinoline-2-carboxylic acid (Figure 1A), is a potent
antibacterial drug. ND has not yet been officially described in
any pharmacopoeia. Mometasone furoate (MF), a glucocorti-
coid, chemically 9a,21-dichloro-llb-hydroxy-16a-methyl 3,20-
dioxopregna-l,4-dien-17-yl furan-2-carboxylate (Figure 1B), is
used for antiinflammatory and antipruritic properties [1,2].
Miconazole nitrate (MN), is an antifungal drug, chemically
known as (RS)-1-[2-(2,4dichlorophenylmethoxy)-2-(2,4-
dichlorophenyl)ethyl] lH-imidazole nitrate (Figure 1C). It is
used to exhibit a broad spectrum of antimicrobial activity for
systemic and local treatment of vaginal and topical fungal
infections [3]. A combination of all these three drugs available
as a cream has been used for the treatment of dermatoses
topically.
A literature survey revealed various stabilities, indicating
reverse-phase high-performance liquid chromatography
(HPLC) and spectrophotometric methods for MF and MN, and
HPLC and high-performance thin-layer chromatographic
(HPTLC) methods for all three drugs individually and in com-
bination with other drugs [4e23]. Spectrophotometric and
HPTLC methods for all three drugs individually and in com-
bination for simultaneous estimation have also been reported
[24e29]. However, development of a HPTLC method for
simultaneous estimation of ND, MF, and MN in combined
dosage form has not been reported.
Recently, HPTLC is widely employed for the quantification
of drugs because of low maintenance cost, lower analysis
time, lowmobile phase consumption per sample, and need for
minimal sample clean-up. It facilitates automated application
of samples and scanning of plates and, moreover, HPTLC as
method recently has been proposed to be included in various
pharmacopoeia [30e33].
Analytical quality by design (AQbD) is a systematic
approach ofmethod development that begins with predefined
objectives and emphasizes method understanding and its
performance, based on sound science and quality risk man-
agement [34]. The main objective of AQbD is to reduce varia-
tions in the measurements by controlling various factors thatFigure 1 e (A) Chemical structures of nadifloxacin; (B)
mometasone furoate; (C) miconazole nitrate.affect method performance thereby resulting in less variation
in interlaboratory studies and assuring reproducibility. Design
of experiment (DoE) is an integral part of AQbD that includes
use of experimental design, mathematical model generation
by ANOVA analysis, and graphical representations, showing
correlation between factors and response [35e38]. Therefore,
design of experimentation is required to study the effect of
previously identified factors affecting the method and
defining a robust AQbD design spacewhere themethod can be
operated anywhere in that region. Method transfer and
reproducibility in interlaboratory studies are the potential
benefits of AQbD [39e40].
This research article focuses on the determination of
robustness of HPTLC analytical method by fractional factorial
design (FFD). Among the various experimental designs, FFD as
a response surface was preferred for prediction of nonlinear
response and also due to its flexibility, in terms of experi-
mental runs and information related to the factor's main and
interaction effects. Therefore a novel, simple, accurate,
reproducible HPTLC method was developed for simultaneous
estimation of ND,MF, andMN in pharmaceutical dosage form,
using FFD design for robustness testing. Therefore, this
research paper describes the development of HPTLC method
for simultaneous estimation of ND, MF, and MN using the DoE
approach for method validation.2. Materials and methods
2.1. Materials
Working standards of ND and MN were kindly provided as a
gratis sample from Hetero Drugs Limited, Hyderabad, India
and MF from Cipla Ltd., Mumbai, India. All solvents and
chemicals used were purchased from Merck Specialities Pvt.
Ltd., India. Marketed cream formulation; Bactimax cream
(Ajanta Pharma Ltd., Mumbai) used in this studywas procured
from the local market.2.2. Instrumentation
Linomat 5 applicator (Camag, Switzerland), twin trough
chamber (20  10 cm; Camag, Switzerland), TLC scanner IV
(Camag, Switzerland), win CATS version 1.4.6 software
(Camag, Switzerland), Microsyringe (Linomat syringe
659.0014, HamiltoneBonaduz Schweiz, Camag, Switzerland),
UV chamber (Camag, Switzerland), precoated silica gel 60F254
aluminium plates (20  10 cm, 100 mm thickness; Merck,
Darmstadt, Germany) were used in the study.2.3. Preparation of standard solutions
A stock solution of ND, MF, and MN was prepared separately
by weighing accurately 10 mg of drug followed by dissolution
in methanol in a 100-mL volumetric flask and dilution up to
the mark with methanol, to obtain a concentration of 100 mg/
mL. This stock solution was appropriately diluted with
methanol to obtain a working standard solution for ND, MF,
and MN.
Table 1 e Experimental factors and levels used in FFD.
Factors High level Low level
Methanol volume in mobile
phase composition (mL) (A)
1.2 0.8
Chamber saturation time (min) (B) 22 18
Wavelength (nm) (C) 226 222
Solvent front (cm) (D) 8.7 8.5
FFD ¼ fractional factorial design.
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Suitable volumes of standard and sample solutions were
applied to the HPTLC plates, 10 mm from the bottom and
15 mm from the side edges in the form of bands with band
length of 6 mm on precoated silica gel aluminum plate 60F254,
(10  10 cm) 100 mm thickness; using a Camag Linomat V
sample applicator. The mobile phase consisted of meth-
anol:ethyl acetate:toluene:acetonitrile:3M ammonium
formate in water (1:2.5:6.0:0.3:0.2, % v/v) and the length of
chromatographic run was 8.5 cm. Mobile phase components
were mixed prior to use and the development chamber was
left to saturate with mobile phase vapor for 20 minutes before
each run. Development was carried out by the ascending
technique to a migration distance of 85 mm. TLC plates were
then dried in a current of air with an air dryer. Densitometric
scanning was performed and all measurements were made in
the reflectance absorbance mode at 224 nm, slit dimension
(6.0  0.30 mm, micro), scanning speed 20 mm/s, data reso-
lution 100 mm/step, optical filter (second order), filter factor
(Savitsky golay 7). The source of radiation was deuterium
lamp emitting a continuous UV spectrum between 200 nm
and 400 nm. Concentration of the drug was determined from
the intensities of diffusely reflected lights. Evaluation was via
peak areas with linear regression analysis.
2.5. Method validation
The method was validated in accordance with ICH guidelines
Q2 (R1) for evaluation of various parameters that include
linearity, precision, accuracy, limit of detection, limit of
quantitation, specificity, and robustness [41]. Linear relation-
ship between peak area and concentration of all three drugs
were evaluated by making five replicate measurements in the
concentration range, 400e2400 ng/band for ND and MN, and
100e600 ng/band for MF respectively. Calibration plots were
constructed using the method of ordinary regression analysis
for checking linearity. Homoscedasticity of variance was also
evaluated for the response by Bartlett's test. Precision of the
developed method was evaluated by performing repeatability
and intermediate precision studies. Repeatability on same day
and intermediate precision on different days was carried out
by performing three replicates of three different concentra-
tions (800 ng, 1600 ng, and 2400 ng) of ND and MN and (200 ng,
400 ng, and 600 ng) of MF. The analysis was repeated in trip-
licate and %RSD was calculated for peak area. Accuracy of the
method was ascertained by performing recovery at three
levels (50%, 100%, and 150%). Recovery studies were carried
out by spiking three different amounts of ND, MN, (400 ng,
800 ng, and 1200 ng) and MF standard (100 ng, 200 ng, and
300 ng) to the dosage form for ND and MN (800 ng/band) and
for MF (200 ng/band) by standard addition method. Recovery
studies were performed in triplicate. As per ICH guidelines,
limit of detection and quantification of the developed method
were calculated from the standard deviation of the response
and slope of the calibration curve of ND, MF, andMN using the
formula, limit of detection ¼ 3.3 * s/S; limit of
quantitation ¼ 10 * s/S where, “s” is standard deviation of
response; and “S” is slope of calibration curve. The specificity
of the method was ascertained by analyzing peak purity ofstandard drug and cream formulation. The spot for ND, MF,
and MN in sample was confirmed by comparing the Rf and
spectra of all the three drugs with that of standard. The peak
purity of each of the three drugs was assessed by comparing
the spectra at three different levels, i.e., peak start (S), peak
apex (M), and peak end (E) position of the spot.
The robustness of an analytical procedure refers to its
capability to remain unaffected by small and deliberate vari-
ations in method parameters. To study robustness, fractional
factorial design (FFD) was applied; four factors half fractional
design (241). In the present study, four factors were selected
based on the criticality of factors observed during trial runs,
chromatographic intuition and experience gained from pre-
vious studies, volume of methanol in the mobile phase
composition (A), chamber saturation time (B), wavelength (C),
and solvent front (D). To quantitatively analyze the deviation
of the considered response, Rf from the original value, the
ranges of factors examined were deliberately changed from
the optimum method settings of all three drugs. The four
factors with their deliberate changes in terms of high and low
level are as shown in Table 1. All experiments were performed
in randomized order to minimize the bias effects of uncon-
trolled factors according to the experimental domain of the
selected variables. The experiments were performed based on
the experimental domain and the responses were recorded in
the form of retention factor of ND, MF, and MN to check the
robustness of the method.
2.6. Analysis of marketed formulation
Marketed formulation (Bactimax cream), an accurately
measured amount of cream (0.5 g) equivalent to 1.0% w/w of
ND, 0.1%w/w of MF, and 2.0% w/w of MNwas transferred into
100 mL volumetric flask followed by addition of 30 mL meth-
anol. The solution was sonicated for 20 minutes and the vol-
ume was made up to the mark with methanol and again
sonicated for 10 minutes. The solution was filtered using
whatman paper 0.45 mm, and 1 mL was further diluted to
10mLwithmethanol. The resultant sample solutionwas used
for chromatographic development and scanning followed by
analysis. The analysis was repeated in triplicate.
2.7. Statistical analysis
All data analysis of experimental design was performed by
using the Design-Expert crack version 7.0.0 (Stat-Ease Inc.,
Minneapolis, USA) and remaining statistical calculations were
performed by use of Microsoft Excel 2013 software (Microsoft
Corporation, USA). Bartlett's test and test for lack of fit were
Figure 2 e TLC chromatogram of standards: ND (Rf 0.23), MF (Rf 0.70), and MN (Rf 0.59). MF ¼ mometasone furoate;
MN ¼ miconazole nitrate; ND ¼ nadifloxacin; TLC ¼ thin layer chromatography.
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moscedasticity of variance and deviation from linearity [42].3Result and discussion
The common detection wavelength selected for analysis was
224 nm as all three drugs were showing optimum response at
224 nm. Mobile phase optimization was carried out in
different solvent systems and different ratios of various sol-
vents were tried such as n-hexane, toluene, methanol, ethylTable 2 e Analytical validation parameters of proposed HPTLC
Analytical parameters ND
Calibration rangea (ng/band) 400e2400
Regression equation 4.5482x þ 2460.7
Coefficient of determination (r2) 0.9976
Standard deviation of slope 0.0056
Confidence limit of slopeb 4.55e4.56
Standard deviation of intercept 6.64
Confidence limit of interceptb 2446.59e2460.32
Limit of detection (ng/band) 9.57
Limit of quantification (ng/band) 29.00
Precision study
Repeatabilityc 0.54e1.49
Interday precisionc (d 1) 1.06e1.63
Interday precisionc (d 2) 1.16e1.61
Accuracyc (%) 98.35e99.76
Bartlett's testd(c2) 0.00019
HPTLC ¼ high performance thin layer chromatography; MF ¼mometaso
a Mean of three determinations.
b Confidence interval at 95% confidence level and four degree of freedom
c n ¼ 3 replicates.
d Calculated value c2 less than critical value c2(0.05, 4) ¼ 9.488.acetate, acetonitrile, diethyl ether, chloroform, and dichloro-
methane. From these, combinations of methanol, ethyl ace-
tate, and toluene gave good results in terms of separation and
therefore, further trials were initiated for different ratios of
methanol, ethyl acetate, and toluene with addition of
different modifiers such as glacial acetic acid, ammonia, for-
mic acid, ortho phosphoric acid, and ammonium formate.
Band characteristic was improved by addition of acetonitrile
to the above mobile phase. However, considerable fronting
was observed in ND, and therefore 3M ammonium formate
was added to minimize fronting. Finally, the mobile phasemethod for simultaneous estimation of ND, MF, and MN.
MF MN
100e600 400e2400
7.6661x þ 357.79 3.5916x þ 1285
0.996 0.9964
0.0626 0.0527
7.60e7.73 3.58e3.65
16.35 48.73
340.87e374.68 1234.68e1335.47
7.03 44.77
21.32 135.69
0.37e1.17 0.15e1.14
0.72e1.56 0.95e1.20
0.75e1.65 1.09e1.17
99.36e99.65 99.16e100.25
0.00113 0.003
ne furoate; MN ¼ miconazole nitrate; ND ¼ nadifloxacin.
.
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ammonium formate in water (1:2.5:6.0:0.3:0.2% v/v/v/v) gave a
sharp and symmetrical peak. Well defined bands of ND at Rf
0.23 ± 0.02 (1200 ng/band), MF at Rf 0.70 ± 0.02 (300 ng/band),
and MN at Rf 0.59 ± 0.05 (1200 ng/band) were obtained when
the chamber was saturated with the mobile phase for 20 mi-
nutes at room temperature and detection wavelength was
224 nm (Figure 2).
ND, MF, and MN showed a good coefficient of determina-
tion in the given concentration range of 400e2400 ng/band for
ND and MN and 100e600 ng/band for MN respectively (Table
2). Homoscedasticity of variance was confirmed by Bartlett's
test and the response of peak area for all three drugs showed
homogenous variance that was exemplified by the c2 value
less than the tabulated value (Table 2). Limits of detection for
ND, MF, and MN were found to be 9.57 ng/band, 7.03 ng/band,
and 44.77 ng/band respectively. Limits of quantitation for ND,
MF, and MN were found to be 29.00 ng/band, 21.32 ng/band,
and 135.69 ng/band respectively indicating good sensitivity of
the method.Figure 3 e TLC chromatogram of formulation, showing peaks o
MN ¼ miconazole nitrate; ND ¼ nadifloxacin; TLC ¼ thin layerThe precision of the developed method was evaluated by
repeatability and intermediate precision, and was expressed
as %RSD of peak area. Repeatability and intermediate preci-
sion was carried out by performing three replicates of three
different concentrations (800 ng, 1600 ng, and 2400 ng for ND
and MN, 200 ng, 400 ng, and 600 ng for MF) showed %RSD < 2%
(Table 2), indicating acceptable precision in terms of repeat-
ability of peak area measurement and sample application. An
accuracy study by standard addition method showed per-
centage recovery at all three levels in the range of
98.35e100.25%, suggesting suitability and applicability of
method for routine drug analysis (Table 2).
The marketed formulation using the developed method,
showed three peaks at Rf of 0.20, 0.70, and 0.59 for ND, MF, and
MN that was found to be at the same Rf for all three respective
standards (Figure 3). The peak purity of ND, MF, and MN in
marketed formulations when evaluated by comparing the
spectra at peak start, peak apex, and peak end positions of the
band (Figures 3Ae3C) showed good correlation i.e., r (S,M) and
r (M,E) for ND was 0.9993 and 0.9960, for MF 0.9993 and 0.9985,f ND, MF, and MN. MF ¼ mometasone furoate;
chromatography.
Figure 4 e In situ overlaid spectra of samples with standard showing peak purity, ND (A), MF (B), and MN (C).
MF ¼ mometasone furoate; MN ¼ miconazole nitrate; ND ¼ nadifloxacin.
Figure 5 e Pareto chart showing the effect of factors and interaction on Rf values of ND (A), MF (B), and MN (C).
MF ¼ mometasone furoate; MN ¼ miconazole nitrate; ND ¼ nadifloxacin.
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Figure 6 e Perturbation plot showing effect of factors on Rf values of ND (A), MF (B), and MN (C). MF ¼mometasone furoate;
MN ¼ miconazole nitrate; ND ¼ nadifloxacin.
Figure 7 e Three-dimensional response surface plot showing effect of factors on Rf values of ND (A), MF (B), and MN (C).
MF ¼ mometasone furoate; MN ¼ miconazole nitrate; ND ¼ nadifloxacin.
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Table 3 e Predicted response models and statistical parameters by ANOVA analysis.
Response
(Rf value)
Polynomial equation model for retardation factor Model p value % CV Adequate precision
ND 0.21 þ 0.019*A þ 0.019*B þ 0.00375*C þ 0.014*D þ 0.00625
*A*C þ 0.00625*A*D
0.0746 1.67 33.26
MF 0.73 þ 0.015*A þ 0.015*Be0.0050*C þ 0.005*D0.0025*A*B þ 0.0075*A*C 0.1951 0.97 11.34
MN 0.55 þ 0.046*A0.0625*B0.00375*C þ 0.00875*D þ 0.00375*A*B
0.00375*A*C
0.0489 0.65 39.31
Bold values signify the adequate precision value must be greater than 4 indicates greater signal to noise ratio.
ANOVA ¼ analysis of variance; CV ¼ coefficient of variance; MF ¼ mometasone furoate; MN ¼ miconazole nitrate; ND: nadifloxacin.
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found to be specific in the presence of various excipients
(Figures 4Ae4C).
All robustness testing runs were performed in a random-
ized order to minimize the effects of uncontrolled factors that
may introduce bias to the response. Graphical interpretation
in form of response surfaces and perturbation plots showed
the correlation of the effect of the factors on the retention
factor of each drug. Perturbation plots reveal the change in
response from its nominal value with all other factors held
constant at a reference point, and steepest slope or curvature
indicates sensitiveness to specific factors.
The Pareto chart is useful for checking the significance of
factors, where effects above the Bonferroni Limit are almost
certainly significant; effectsabove the t-value limit arepossibly
significant and effects below the t-value limit are not likely to
be significant. The Pareto chart for all the three drugs reveals
that volume of methanol in mobile phase had important ef-
fects on retention factor of drugs, in decreasing order: for ND,
A > B > D > AC > AD; for MF, A > B > AC > C > D; and for MN,
A > D > B > C ¼ AB ¼ AC, as shown in Figures 5Ae5C.
Perturbation plots indicated that small variation in volume
of methanol and chamber saturation time had important ef-
fects but did not produce any significant effect on retention
factor except MN as shown in Figures 6Ae6C. As can be seen
from the three-dimensional response surface plots, an in-
crease in methanol content of mobile phase produced an in-
crease in Rf of all three drugs as shown in Figures 7Ae7C.
The model was validated by analysis of variance (ANOVA)
using Design Expert software (Table 3). The equation in terms
of coded factors can be used tomake predictions regarding the
response for given levels of each factor. The coded equation is
useful for identifying the relative impact of the factors by
comparing the factor coefficients. Model p value > 0.05Table 4 e Analysis of pharmaceutical formulation.
Drug Label claim
(% w/w)
% Amount of
drug founda
% RSD
ND 1% w/w 99.73 0.64
MF 0.1% w/w 97.05 1.27
MN 2% w/w 99.67 0.35
%RSD ¼ relative standard deviation; FFD ¼ fractional factorial
design; MF ¼ mometasone furoate; MN ¼ miconazole nitrate;
ND ¼ nadifloxacin.
a Mean of three determinations.indicates that factors had nonsignificant effect on response
resulting in a robust method. Adequate precision defined as a
signal-to-noise ratio > 4 is desirable, and the obtained ratio for
all the three drugs indicated an adequate signal (Table 4). The
low standard deviation [% coefficient of variance (CV)] and
adequate precision, indicates a good relationship between the
experimental data and those of the fitted models.
The cream formulation, Bactimax (7.5g), containing ND
(1%), MF (0.1%), andMN (2%) when analyzed in triplicate using
the developed HPTLC method showed good recovery where
percentage amount for all the drugs were within the range of
97.05%e99.73% with %RSD < 2 (Table 4) indicating that the
method can be applicable in routine quality control testing of
the cream.
The developed method was found to be novel, simple, ac-
curate, precise, specific, and reproducible for the simultaneous
estimation of ND, MF, and MN in cream formulations. More-
over, the major advantage of developed HPTLC method is that
several samples can be run simultaneously using a small
amount of mobile phase unlike HPLC, thus lowering analysis
time by high sample throughput and cost per analysis. The
application of FFD on robustness was to study simultaneous
variation of effects on responses. Methanol content in mobile
phase appeared to havepossibly significant effects on response
of MN and non significant effects on response of ND and MF in
robustness study compared with other factors and therefore it
was important tobecarefullycontrolled. It is concludedthat the
use of experimental design and response surface methodology
is a flexible procedure, able to reduce the number of the needed
experiments for the robustness study of HPTLC method. The
method was found to be repeatable and suitable for routine
quality control and combined dosage form analysis.Conflicts of interest
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